DR. IMADUL ISLAM
Dr. Imadul Islam has more than 25 years of experience in discovery and development of new chemical entity (NCE) and management of drug discovery programs at major pharmaceutical companies. Dr. Imad is currently employed as senior research scientist, deputy director-drug discovery and head of pharmaceutical analysis section at King Abdullah International Medical Research Center (KAIMRC), National Guard Health Affairs in Riyadh, Kingdom of Saudi Arabia.
Prior to joining KAIMRC, Dr. Imad was director of CNS pre-clinical drug discovery at Bristol-Myers Squibb-Biocon Research Center (BBRC) in Bangalore, India. Dr. Imad was investigator at Glaxo Smith Kline (GSK), Singapore, in CNS pre-clinical drug discovery prior to BMS. Dr. Imad held position of escalating responsibilities at Berlex Biosciences (Bayer/Schering), California, USA in the drug discovery group and was involved in preclinical and clinical research in oncology, immunology/ inflammation, and cardiovascular therapeutic areas. During his tenure at Bayer, one small molecules progressed into phase II for inflammation disorders and several molecules has been out licensed to major pharmaceutical companies. Dr. Imad was scientist at Synaptic Pharmaceutical (Lundbeck), USA working in the area of metabolic diseases like obesity, which resulted in major collaboration with Novartis discovering novel NPY5 antagonists. Dr. Imad was associate research scientist at Arizona State University, USA and Upjohn Pharmaceuticals (Pfizer) Kalamazoo, USA. To his credit, Dr. Imad has 33 issued US patents and 40 peer reviewed publications and several preclinical and clinical candidates. Dr. Imad has rich experience in collaborating with academia and industry. Also, he serves as reviewer of many drug discovery and medicinal chemistry journals. Dr. Imad current area of interest is antibody drug conjugates (ADC) for treatment of cancer, application of ADC in immunological and inflammatory disorders and de novo design of new anti-cancer compounds